Chronic Urticaria Or Hives - Pipeline Review, H1 2015

Published: May, 2015 | Pages: 71 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Chronic Urticaria Or Hives - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Chronic Urticaria Or Hives - Pipeline Review, H1 2015', provides an overview of the Chronic Urticaria Or Hives's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chronic Urticaria Or Hives, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Urticaria Or Hives and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chronic Urticaria Or Hives
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Chronic Urticaria Or Hives and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Chronic Urticaria Or Hives products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chronic Urticaria Or Hives pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reason to Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chronic Urticaria Or Hives
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chronic Urticaria Or Hives pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Chronic Urticaria Or Hives Overview 7
Therapeutics Development 8
Pipeline Products for Chronic Urticaria Or Hives - Overview 8
Pipeline Products for Chronic Urticaria Or Hives - Comparative Analysis 9
Chronic Urticaria Or Hives - Therapeutics under Development by Companies 10
Chronic Urticaria Or Hives - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Chronic Urticaria Or Hives - Products under Development by Companies 14
Chronic Urticaria Or Hives - Companies Involved in Therapeutics Development 15
AstraZeneca PLC 15
Biofrontera AG 16
Bristol-Myers Squibb Company 17
ELORAC, Inc. 18
F. Hoffmann-La Roche Ltd. 19
FAES Farma SA 20
Genentech, Inc. 21
GlaxoSmithKline plc 22
Merck & Co., Inc. 23
Panacea Biotec Limited 24
Chronic Urticaria Or Hives - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
abatacept (recombinant) - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
AZD-1981 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
BF-Derm-1 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
bilastine - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
cidoxepin hydrochloride - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
desloratadine - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
GSK-2646264 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
JDP-205 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
omalizumab - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
omalizumab biosimilar - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
quilizumab - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Chronic Urticaria Or Hives - Recent Pipeline Updates 49
Chronic Urticaria Or Hives - Dormant Projects 56
Chronic Urticaria Or Hives - Discontinued Products 57
Chronic Urticaria Or Hives - Product Development Milestones 58
Featured News & Press Releases 58
Aug 28, 2014: Novartis announces that Xolair is approved in Canada as a licensed therapy for chronic idiopathic urticaria (CIU) patients unresponsive to antihistamines 58
May 07, 2014: FDA Approves Xolair for Treatment of Chronic Hives 59
Mar 21, 2014: Novartis announces US FDA approval of Xolair for chronic idiopathic urticaria 59
Mar 06, 2014: Novartis announces Xolair approved in EU as first and only licensed therapy for chronic spontaneous urticaria patients unresponsive to antihistamines 60
Jan 24, 2014: Novartis reports positive opinion from CHMP for Xolair in severe form of skin disease CSU, a debilitating form of hives and chronic itch 62
Oct 11, 2013: FDA Files Genentech's Supplemental Biologics License Application of Xolair for Chronic Idiopathic Urticaria 64
Sep 30, 2013: Novartis to reveal landmark Phase III results of omalizumab at upcoming EADV 2013 congress 64
Jun 26, 2013: Novartis Reports New Phase III Data Showing Omalizumab Significantly Improves Itch In Patients With Severe Form Of CSU 66
Mar 20, 2013: Omalizumab Shows Promise In Eliminating Symptoms Of Chronic Urticaria, Study Finds 67
Feb 24, 2013: Genentech Reports Omalizumab Meets Primary Endpoint In Phase III Results In Patients With Chronic Form Of Hives Who Failed Standard Therapy 68
Appendix 70
Methodology 70
Coverage 70
Secondary Research 70
Primary Research 70
Expert Panel Validation 70
Contact Us 70
Disclaimer 71

List of Tables

Number of Products under Development for Chronic Urticaria Or Hives, H1 2015 8
Number of Products under Development for Chronic Urticaria Or Hives - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Comparative Analysis by Late Stage Development, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Chronic Urticaria Or Hives - Pipeline by AstraZeneca PLC, H1 2015 15
Chronic Urticaria Or Hives - Pipeline by Biofrontera AG, H1 2015 16
Chronic Urticaria Or Hives - Pipeline by Bristol-Myers Squibb Company, H1 2015 17
Chronic Urticaria Or Hives - Pipeline by ELORAC, Inc., H1 2015 18
Chronic Urticaria Or Hives - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 19
Chronic Urticaria Or Hives - Pipeline by FAES Farma SA, H1 2015 20
Chronic Urticaria Or Hives - Pipeline by Genentech, Inc., H1 2015 21
Chronic Urticaria Or Hives - Pipeline by GlaxoSmithKline plc, H1 2015 22
Chronic Urticaria Or Hives - Pipeline by Merck & Co., Inc., H1 2015 23
Chronic Urticaria Or Hives - Pipeline by Panacea Biotec Limited, H1 2015 24
Assessment by Monotherapy Products, H1 2015 25
Number of Products by Stage and Target, H1 2015 27
Number of Products by Stage and Mechanism of Action, H1 2015 29
Number of Products by Stage and Route of Administration, H1 2015 31
Number of Products by Stage and Molecule Type, H1 2015 33
Chronic Urticaria Or Hives Therapeutics - Recent Pipeline Updates, H1 2015 49
Chronic Urticaria Or Hives - Dormant Projects, H1 2015 56
Chronic Urticaria Or Hives - Discontinued Products, H1 2015 57